Full Text View
Tabular View
No Study Results Posted
Related Studies
Prospective Double-Blinded Randomized Controlled Trial of 12-Weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients
This study is currently recruiting participants.
Study NCT00517114   Information provided by Hospital Authority, Hong Kong
First Received: August 15, 2007   Last Updated: June 23, 2009   History of Changes

August 15, 2007
June 23, 2009
January 2005
 
Symptoms assessment, quality of life. [ Time Frame: 12 weeks ]
Same as current
Complete list of historical versions of study NCT00517114 on ClinicalTrials.gov Archive Site
  • Compliance [ Time Frame: 4 weeks ]
  • Adverse effects [ Time Frame: 4 weeks ]
Same as current
 
Prospective Double-Blinded Randomized Controlled Trial of 12-Weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients
Prospective Double-Blinded Randomized Controlled Trial of 12-Weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients

The purpose of this study is to evaluate the efficacy of rabeprazole (pariet) versus placebo in treating reflux laryngitis in Chinese patients. Patients who attend the voice clinic of Department of ENT, Queen Mary hospital with suspected reflux laryngitis will be recruited. A questionnaire will be administered by the research assistant of the Department of Medicine and ENT, Queen Mary hospital. A 12-week course of PPI versus placebo trial will be commenced and patients' symptoms and signs will be documented at 6-week and 12-week time. The study will finish after a 12-week course of rabeprazole.

 
 
Interventional
Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
  • Gastroesophageal Reflux
  • Laryngitis
Drug: Rabeprazole 20mg twice daily
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
200
December 2008
 

Inclusion Criteria:

  • Ambulatory patients with age between 18-80 years old
  • Patients with newly presented laryngitis.

Exclusion Criteria:

  • They were under 18 or over 80 years of age
  • Has significant concomitant medical disease
  • Pregnancy or lactating women
  • Chronic cough attributable to known chronic pulmonary or tracheobronchial disease
  • Previous glottal surgery, radiotherapy or malignancy
  • Acid suppressive therapy within 4 wk prior to recruitment
  • Pharyngo-laryngeal infection in the previous 3 months
  • Tracheal intubation in previous 12 months
  • Immunosuppression and use of inhaled corticosteroid
Both
18 Years to 80 Years
 
Contact: Ting Kin Cheung, Dr (852) 2855 3989 cheungtk@hkucc.hku.hk
China
 
NCT00517114
 
UW04-204 T/526, HARECCTR0500033
Hospital Authority, Hong Kong
The University of Hong Kong
Principal Investigator: Paul KY Lam, Dr Department of Medicine, Queen Mary Hospital/ The University of Hong Kong
Hospital Authority, Hong Kong
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP